SPOTLIGHT: FDA plans stent review


The FDA will review Medtronic's drug-coated stent (called "Endeavor") next month, considering information from 4,100 patients in clinical trials as long as four years, the company said. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.